Search Page

1

Cite

Share

The voltage-dependent sodium channel in mammalian CNS and PNS antibody characterization and immunocytochemical localization. Brain Research 532 (1990) 222-231.

Elmer LW, Black JA, Waxman SG. Elmer LW, et al. Brain Res. 1997 Jun 27;761(1):2. doi: 10.1016/s0006-8993(97)00545-3. Brain Res. 1997. PMID: 9247058 No abstract available.

Cite

Share

2

Cite

Share

Sodium channels in astrocytes of rat optic nerve in situ: immuno-electron microscopic studies.

Black JA, Friedman B, Elmer LW, Waxman SG. Black JA, et al. Among authors: elmer lw. Glia. 1999 Oct;28(1):84. Glia. 1999. PMID: 10498826 No abstract available.

Cite

Share

3

Cite

Share

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE. Espay AJ, et al. Among authors: elmer lw. Neurol Clin Pract. 2017 Feb;7(1):86-93. doi: 10.1212/CPJ.0000000000000316. Neurol Clin Pract. 2017. PMID: 28243505 Free PMC article. Review.

Cite

Share

4

Cite

Share

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.

Elmer LW, Bertoni JM. Elmer LW, et al. Expert Opin Pharmacother. 2008 Nov;9(16):2759-72. doi: 10.1517/14656566.9.16.2759. Expert Opin Pharmacother. 2008. PMID: 18937611 Review.

Cite

Share

5

Cite

Share

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.

Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, Felt L, Johnson R, Patni R. Elmer LW, et al. CNS Drugs. 2018 Apr;32(4):387-398. doi: 10.1007/s40263-018-0498-4. CNS Drugs. 2018. PMID: 29532440 Free PMC article. Clinical Trial.

Cite

Share

6

Cite

Share

Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.

Hauser RA, Kremens DE, Elmer LW, Kreitzman DL, Walsh RR, Johnson R, Howard R, Nguyen JT, Patni R. Hauser RA, et al. Among authors: elmer lw. J Parkinsons Dis. 2019;9(3):591-600. doi: 10.3233/JPD-181565. J Parkinsons Dis. 2019. PMID: 31081793 Free PMC article. Clinical Trial.

Cite

Share

7

Cite

Share

Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.

Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, Felt L, Johnson R, Patni R. Elmer LW, et al. CNS Drugs. 2018 Apr;32(4):399-400. doi: 10.1007/s40263-018-0510-z. CNS Drugs. 2018. PMID: 29637528 Free PMC article.

Cite

Share

8

Cite

Share

A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.

Nicholas AP, Borgohain R, Chaná P, Surmann E, Thompson EL, Bauer L, Whitesides J, Elmer LW; SP921 Study Investigators. Nicholas AP, et al. Among authors: elmer lw. J Parkinsons Dis. 2014;4(3):361-73. doi: 10.3233/JPD-130320. J Parkinsons Dis. 2014. PMID: 24643203 Clinical Trial.

Cite

Share

9

Cite

Share

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.

LeWitt PA, Poewe W, Elmer LW, Asgharnejad M, Boroojerdi B, Grieger F, Bauer L. LeWitt PA, et al. Among authors: elmer lw. Clin Neuropharmacol. 2016 Mar-Apr;39(2):88-93. doi: 10.1097/WNF.0000000000000133. Clin Neuropharmacol. 2016. PMID: 26882318 Free PMC article. Clinical Trial.

Cite

Share

10

Cite

Share

Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.

Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R. Lyons KE, et al. Among authors: elmer lw. Clin Neuropharmacol. 2010 Jan-Feb;33(1):5-10. doi: 10.1097/WNF.0b013e3181b7926f. Clin Neuropharmacol. 2010. PMID: 19855267 Clinical Trial.

Cite

Share